Mesa, AZ
Ketamine Therapy clinics in Mesa
Ketamine therapy in Mesa is delivered through psychiatry-led clinics, anesthesia-run infusion centers, and ketamine-assisted psychotherapy practices, with hospital referrals often tied to Banner Desert Medical Center and Mountain Vista Medical Center. Demand reflects a large East Valley family and retiree population and an active local market for treatment-resistant depression, PTSD, and chronic pain.
The strongest evidence supports intranasal esketamine (Spravato, FDA-approved for treatment-resistant depression) and intravenous racemic ketamine (off-label, substantial supporting evidence). Clinics in Mesa, Arizona also offer intramuscular, sublingual, and at-home oral lozenge protocols, with weaker evidence and variable safety oversight. Arizona's relatively permissive regenerative medicine climate shapes which clinics can operate as cash-pay versus insurance-eligible.
With ketamine clinics on Regenerated.com in Mesa, patients can compare whether the clinic offers psychiatric evaluation, anesthesia monitoring during infusion, and structured preparation and integration.
Keystone Medical Wellness Eastmark
- NAD IV Therapy
- Vitamin IV Therapy
- IV Therapy
- Laser Therapy (LLLT)
- Ketamine Therapy
Combat Medic Wellness
- NAD IV Therapy
- Vitamin IV Therapy
- Ketamine Therapy
- Peptide Therapy
- Testosterone Replacement Therapy (TRT)
Mesquite Valley Integrated Health
- Transcranial Magnetic Stimulation (TMS)
- Ketamine Therapy
Mountain View Headache and Spine Institute
- IV Therapy
- Ketamine Therapy
- Arthritis Treatment
- Stem Cell Therapy
Infusion for Health
- NAD IV Therapy
- Vitamin IV Therapy
- IV Therapy
- Multiple Sclerosis (MS) Treatment
- Ketamine Therapy
Precision Integrative Specialists & Oncology
- PRP Therapy
- Ozone Therapy
- IV Therapy
- Hyperbaric Oxygen Therapy (HBOT)
- Ketamine Therapy
Family Allergy Clinic and Wellness Center
- NAD IV Therapy
- Vitamin IV Therapy
- PRP Therapy
- IV Therapy
- IV Hydration
Regulatory context
A note on Arizona's ketamine therapy rules.
Ketamine is a DEA Schedule III controlled substance, FDA-approved as a dissociative anesthetic and used off-label for treatment-resistant depression, PTSD, and chronic pain. The FDA approved esketamine (Spravato) in 2019 for treatment-resistant depression under a Risk Evaluation and Mitigation Strategy (REMS) program that requires in-office administration at certified sites. MDMA-assisted therapy remains Schedule I; the FDA issued a Complete Response Letter in August 2024 to Lykos Therapeutics on its MDMA new drug application. Psilocybin is Schedule I and holds FDA Breakthrough Therapy designation through sponsors such as Compass Pathways and Usona, but has not received FDA approval. Oregon Measure 109 (passed 2020, operational 2023) created a state psilocybin service center framework, and Colorado Proposition 122 (2022) authorized regulated healing centers.
-
Arizona Psilocybin Research Grant (SB 1726, 2023)
Allocated $5 million for whole-mushroom psilocybin clinical research; does not create a therapeutic access framework. -
Arizona Controlled Substances Act
Mirrors federal scheduling outside the research grant program.
Arizona enforces federal DEA scheduling and has not decriminalized psilocybin or MDMA. The Arizona Medical Board and Arizona Board of Osteopathic Examiners oversee prescribing conduct. DEA enforcement on ketamine clinics focuses on compounding sources, diversion, and billing fraud. Ryan Haight Act rules apply to telehealth ketamine prescriptions, with DEA flexibilities extended through 2025.